OncoLattice BioAAI Inc.

Insights

Apex AI and oncology conference article library.

A unified article library combining public Apex AI articles with public oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword with official source links preserved.

Article library

Apex AI and oncology conference article library

A unified library of public Apex AI articles and public oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.

Last synced: Jun 1, 2026

Source: All sources · Topic: All topics · 25 articles · 10 per page

Apex AIAI / Trial strategy
May 29, 2026Source: Apex AI Institute

AI at ASCO 2026: From Topic to Tool

AI tags 220 abstracts, the largest subtrack at ASCO 2026. Most of it is applied to concrete tasks; trial matching is where it meets drug development most directly.

Open AAI article
Apex AITrial strategy / Oncology
May 29, 2026Source: Apex AI Institute

Genitourinary Cancer at ASCO 2026 — Prostate, Bladder, Kidney

Prostate, bladder, and kidney cancer studies from ASCO 2026, organized by cancer, with trial sizes, hazard ratios, response rates, and data tables.

Open AAI article
Apex AIAI / Oncology
May 22, 2026Source: Apex AI Institute

AUA 2026 mPC — Five Trends: Triplet Gradient, PSMA-PET, PSMAddition, Survivorship, AI Gap

Reading 50 advanced and metastatic prostate-cancer abstracts at AUA 2026: triplet gradient, PSMA-PET reclassification, PSMAddition, survivorship-as-section, and what is still missing.

Open AAI article
AACROfficial news release
May 21, 2026Source: AACR News ReleasesSignal: Official news release

Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer

CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis, according to a study published in Clinical Cancer Research. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

Open official source
Apex AIAI
May 15, 2026Source: Apex AI Institute

AUA 2026 — AI and Robots Are Both Here. They Haven't Met Yet.

621 abstracts, one in five. Single-port leads, LLMs arrive, and the AI-robot intersection is nearly empty.

Open AAI article
AACRNews release
May 7, 2026Source: AACR Annual Meeting NewsSignal: News release

AACR CEO Margaret Foti, PhD, MD (hc): Thank you for an incredible AACR Annual Meeting 2026! - AACR Annual Meeting News

The AACR Annual Meeting 2026 featured a spectacular display of the progress that is being made against cancer due to your tremendous efforts. All of you—cancer researchers, clinicians, other health care profes... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

Open official source
AACROfficial news release
May 7, 2026Source: AACR News ReleasesSignal: Official news release

Emerging Frontiers in Oncology to Support AACR and Early-Career Investigators Through Annual Oncology Summit

The American Association for Cancer Research (AACR) today thanked Emerging Frontiers in Oncology (EFO) for its support of the cancer research workforce through fundraising associated with the 8th Annual Emergi... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

Open official source
Apex AIAI / Oncology
May 1, 2026Source: Apex AI Institute

AACR 2026 — Head and Neck Cancer Gets a New Pipeline

358 HNSCC abstracts, new therapeutic architectures, diversifying biomarkers, and three bets against checkpoint-refractory disease.

Open AAI article
AACRNews release / Program
Apr 30, 2026Source: AACR Annual Meeting NewsSignal: News release

Closing Plenary Session examined highlights from the AACR Annual Meeting 2026 - AACR Annual Meeting News

Katerina A. Politi, PhD, identified takeaways emerging from presentations in basic and translational science, including that fundamental insights into cancer biology are revealing new strategies to treat cance... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

Open official source
AACRNews release / Program
Apr 30, 2026Source: AACR Annual Meeting NewsSignal: News release

Fifth Plenary Session spotlighted new treatment modalities transforming the oncology landscape - AACR Annual Meeting News

Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a fo... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.

Open official source